Boston, 11 Dec 2024: A novel, fixed-duration drug combination — consisting of a second-generation BTK inhibitor, called acalabrutinib, plus a BCL-2 inhibitor (venetoclax), with or without a third blood cancer drug — shows deep and durable responses in patients with ch......
View Details

Related News

• Punjab cop arrests man for narcotic drugs case, gets fined by court (11-12-2024)

---

• NPPA Mandates Transparency in Angioplasty Billing with Separate Costs for Non-Stent Components: MoS Anupriya Patel (11-12-2024)

---

• Board of Alkem Laboratories approves transfer of its trade generics biz to Alkem Wellness (11-12-2024)

---

• Instructions for inspection of food manufacturing units (11-12-2024)

---

• PCB levies 31L penalty on pharma manufacturing unit over violations (11-12-2024)

---

• FDI equity inflow into pharma sector grows to $520 million in H1FY25 (11-12-2024)

---

• Govt Expands Jan Aushadhi Kendras in Rural Areas Through PACS Collaboration (11-12-2024)

---

• Unexplained sudden deaths among youth not linked to Covid vaccines: JP Nadda in RS (11-12-2024)

---

• Fake food supplement factory busted, 3 arrested, goods worth Rs 50 lakh seized (11-12-2024)

---

• Fake medicines factory busted in Modinagar, UP (10-12-2024)

---